Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Lung Neoplasms 29Triple Negative Breast Neoplasms 13Breast Neoplasms 13Ovarian Neoplasms 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Neoplasms 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 8Colorectal Neoplasms 5Adenocarcinoma of Lung 5Carcinoma 4Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lung Diseases 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thoracic Neoplasms 2Sarcoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Rectal Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

pembrolizumab 1atezolizumab 1PT-100 dipeptide 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Carboplatin × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡